SynthesisCardiovascular diabetology2017
Lipoprotein(a) and incident type-2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature.
Synthesis in Cardiovascular diabetology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 3 syntheses or guidelines pooled it, 113 citations in OpenAlex.
- Lipid biomarkers for the prediction of type 2 diabetes risk, an umbrella review and updated meta-analyses of prospective observational studies.Frontiers in endocrinology · 2026Pooled it
- Circulating lipoprotein(a) in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis.Journal of gastroenterology and hepatology · 2024Pooled it
- Can biomarkers be used to improve diagnosis and prediction of metabolic syndrome in childhood cancer survivors? A systematic review.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2021Pooled it
- Risk of Incident Diabetes Related to Lipoprotein(a), LDL Cholesterol, and Their Changes With Alirocumab: Post Hoc Analyses of the ODYSSEY OUTCOMES Randomized Trial.Diabetes care · 2025Trial
- Lipoprotein(a) as a Cardiovascular Risk Factor: Clinical Significance and Therapeutic Perspectives.Biomedicines · 2026Review
- Lipoprotein(a) and atherosclerosis risk across estimated glucose disposal rate strata: evaluating synergistic predictive utility.Lipids in health and disease · 2026Article
- Article
- Lipoprotein(a) Reflects Baseline Lipid Phenotype but Does Not Predict Long-Term Cardiometabolic Risk in Apparently Healthy Women.Metabolites · 2026Article
- Lipoprotein(a) in Cardiovascular Diseases and Emerging Therapeutic Strategies.Cardiovascular drugs and therapy · 2026Review
- Lipoprotein(a) Lowering with Pelacarsen (TQJ230).Cardiovascular & hematological disorders drug targets · 2026Review
- Low early-pregnancy serum lipoprotein(a) as an independent associated factor for gestational diabetes mellitus: a retrospective cohort study.Frontiers in endocrinology · 2026Article
- Lp(a) levels and ischemic stroke recurrence in type 2 diabetes mellitus.Diabetology & metabolic syndrome · 2025Article
- Lipoprotein(a) and Cardiovascular Risk in Asian Populations: A Comprehensive Review.Journal of lipid and atherosclerosis · 2025Review
- Prevalence of Lipoprotein(a) Measurement and its Association with Arteriosclerosis in Asymptomatic Individuals in China.Journal of atherosclerosis and thrombosis · 2025Article
- Serum Lipoprotein(a) Levels and Their Association with Atherosclerotic Cardiovascular Disease in Japan.Journal of atherosclerosis and thrombosis · 2025Article
- 2024: The year in cardiovascular disease - the year of lipoprotein(a). Research advances and new findings.Archives of medical science : AMS · 2025Article
- Interaction Between Primary Hyperlipidemias and Type 2 Diabetes: Therapeutic Implications.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Review
- Causal associations between insulin and Lp(a) levels in Caucasian population: a Mendelian randomization study.Cardiovascular diabetology · 2024Article
- Exploring the Interplay between Diabetes and Lp(a): Implications for Cardiovascular Risk.Current diabetes reports · 2024Review
- Genetics and Pathophysiological Mechanisms of Lipoprotein(a)-Associated Cardiovascular Risk.Journal of the American Heart Association · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 4 countries.
Funding
Abstract
aimsWe aimed to (1) assess the association between lipoprotein(a) [Lp(a)] concentration and incident type-2 diabetes in the Bruneck study, a prospective population-based study, and (2) combine findings with evidence from published studies in a literature-based meta-analysis.
methodsWe used Cox proportional hazards models to calculate hazard ratios (HR) for incident type-2 diabetes over 20 years of follow-up in 815 participants of the Bruneck study according to their long-term average Lp(a) concentration. For the meta-analysis, we searched Medline, Embase and Web of Science for relevant prospective cohort studies published up to October 2016.
resultsIn the Bruneck study, there was a 12% higher risk of type-2 diabetes for a one standard deviation lower concentration of log Lp(a) (HR = 1.12 [95% CI 0.95-1.32]; P = 0.171), after adjustment for age, sex, alcohol consumption, body mass index, smoking status, socioeconomic status, physical activity, systolic blood pressure, HDL cholesterol, log high-sensitivity C-reactive protein and waist-hip ratio. In a meta-analysis involving four prospective cohorts with a total of 74,575 participants and 4514 incident events, the risk of type-2 diabetes was higher in the lowest two quintiles of Lp(a) concentrations (weighted mean Lp(a) = 3.3 and 7.0 mg/dL, respectively) compared to the highest quintile (62.9 mg/dL), with the highest risk of type-2 diabetes seen in quintile 1 (HR = 1.28 [1.14-1.43]; P < 0.001).
conclusionsThe current available evidence from prospective studies suggests that there is an inverse association between Lp(a) concentration and risk of type-2 diabetes, with a higher risk of type-2 diabetes at low Lp(a) concentrations (approximately <7 mg/dL).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.